Concept Life Sciences, the integrated drug discovery, development and analytical services company, announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the Alderley Park site.
Matilda Bingham has more than 15 years’ experience in the pharmaceutical industry, in both biotech and pharma environments. She joins Concept from Redx Pharma, where she held positions as Head of Research and Operations, and Executive Director of Oncology and Immunology.
Bingham previously also worked for MSD Research Laboratories (part of Merck). With a PhD in Organic Chemistry, Bingham has had numerous publications, patents and posters published, and has managed programmes from hit-to-lead through to the clinic across a diverse range of target classes and disease areas.
Bingham said: “I am looking forward to applying my own drug discovery experience alongside the already established expertise within the team to expand integrated drug discovery services at Concept, both at the Alderley Park Site and in collaboration with the Company’s other sites. The location and site infrastructure at Alderley provide us with a great opportunity to run integrated projects for customers.”
David Higton is a highly experienced scientist with a proven track record of delivering innovative, effective solutions. He has more than 34 years of expertise in bioanalytical and biotransformation studies, including 23 years at Glaxo Group Research, now GlaxoSmithKline, where he supported pre-clinical, clinical, and discovery investigations, for both non-GLP and GLP studies.
Higton said: “I am excited to be joining the Concept team at Alderley Park, as well as working at the Dundee site to establish biotransformation activities for both cold and labelled material in discovery, pre-clinical and clinical investigations. I am looking forward to bringing my wealth of experience in this area to benefit our clients.”
Higton joins Concept from Cyprotex, where he was most recently Head of Analytical Sciences. Prior to this he was Analytical Team Leader at RedX Pharma, Vice President, Operations at Xceleron and Principal Scientist at AstraZeneca, leading new scientific and technological development in regulatory bioanalysis.
Philip Payne, Chief Operating Officer, Concept Life Sciences, said: “With several years’ experience of managing multidisciplinary research projects in a pharmaceutical company environment, we are delighted to have appointed Matilda to head up our new Alderley Park site, which was established in September 2017. We are also pleased to welcome David, whose expertise will be a valuable addition to the analytical team.”